Ruffer LLP’s Supernus Pharmaceuticals SUPN Stock Holding History

Ruffer LLP’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,327	Closed	-$1.71M	–	233
2025 Q4	$1.71M	Sell	34,327 -21,058	-38%	-$1.02M	0.08%	126
2025 Q3	$2.65M	Buy	+55,385	New	+$2.23M	0.15%	80

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ruffer LLP's SUPN Position: Q1 2026 in Review

Ruffer LLP sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 34,327 shares — an estimated $1.71M sold.

Ruffer LLP first reported a position in SUPN in Q3 2025 and held it in 2 quarters. The position peaked at $2.65M in Q3 2025. 328 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Ruffer LLP reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Ruffer LLP sold 34,327 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.71M.
Ruffer LLP first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Ruffer LLP's Supernus Pharmaceuticals position peaked at $2.65M in Q3 2025.
328 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Ruffer LLP's 13F filing for Q1 2026, filed 13 May 2026.